These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30612340)

  • 1. Reduced gray matter volume in cognitively preserved COMT
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Brain Imaging Behav; 2020 Apr; 14(2):321-328. PubMed ID: 30612340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson's disease.
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Behav Brain Res; 2019 Oct; 372():112039. PubMed ID: 31202861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease.
    Bäckström D; Eriksson Domellöf M; Granåsen G; Linder J; Mayans S; Elgh E; Zetterberg H; Blennow K; Forsgren L
    Acta Neurol Scand; 2018 Jan; 137(1):91-98. PubMed ID: 28869277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.
    Wu K; O'Keeffe D; Politis M; O'Keeffe GC; Robbins TW; Bose SK; Brooks DJ; Piccini P; Barker RA
    Brain; 2012 Aug; 135(Pt 8):2449-57. PubMed ID: 22843413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease.
    Lin CH; Fan JY; Lin HI; Chang CW; Wu YR
    Parkinsonism Relat Disord; 2018 May; 50():48-53. PubMed ID: 29439855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.
    Klebe S; Golmard JL; Nalls MA; Saad M; Singleton AB; Bras JM; Hardy J; Simon-Sanchez J; Heutink P; Kuhlenbäumer G; Charfi R; Klein C; Hagenah J; Gasser T; Wurster I; Lesage S; Lorenz D; Deuschl G; Durif F; Pollak P; Damier P; Tison F; Durr A; Amouyel P; Lambert JC; Tzourio C; Maubaret C; Charbonnier-Beaupel F; Tahiri K; Vidailhet M; Martinez M; Brice A; Corvol JC; ;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):666-73. PubMed ID: 23408064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.
    Paul KC; Rausch R; Creek MM; Sinsheimer JS; Bronstein JM; Bordelon Y; Ritz B
    J Parkinsons Dis; 2016 Apr; 6(2):349-59. PubMed ID: 27061069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.
    Williams-Gray CH; Hampshire A; Barker RA; Owen AM
    Brain; 2008 Feb; 131(Pt 2):397-408. PubMed ID: 18178571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease.
    Xu Y; Yang J; Hu X; Shang H
    J Neurol; 2016 Jun; 263(6):1178-87. PubMed ID: 27113603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZNF804A rs1344706 interacts with COMT rs4680 to affect prefrontal volume in healthy adults.
    Xu Q; Xiong Y; Yuan C; Liu F; Zhao F; Shen J; Qin W; Yu C
    Brain Imaging Behav; 2018 Feb; 12(1):13-19. PubMed ID: 28078547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study.
    Chung J; Ushakova A; Doitsidou M; Tzoulis C; Tysnes OB; Dalen I; Pedersen KF; Alves G; Maple-Grødem J
    Neurosci Lett; 2021 Nov; 764():136243. PubMed ID: 34509566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.
    Zhang Y; Feng S; Nie K; Zhao X; Gan R; Wang L; Zhao J; Tang H; Gao L; Zhu R; Wang L; Zhang Y
    J Neurol Sci; 2016 Oct; 369():347-353. PubMed ID: 27653922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMT-Val158Met polymorphism modulates antipsychotic effects on auditory verbal hallucinations and temporal lobe gray matter volumes in healthy individuals-symptom relief accompanied by worrisome volume reductions.
    Zhuo C; Cheng L; Li G; Xu Y; Jing R; Li S; Zhang L; Lin X; Zhou C
    Brain Imaging Behav; 2020 Oct; 14(5):1373-1381. PubMed ID: 30712251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal study investigating the influence of COMT gene polymorphism on cortical thickness changes in Parkinson's disease over four years.
    Tajerian A
    Sci Rep; 2024 Apr; 14(1):9920. PubMed ID: 38689006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More than an "inverted-U"? An exploratory study of the association between the catechol-o-methyltransferase gene polymorphism and executive functions in Parkinson's disease.
    Fang YJ; Tan CH; Tu SC; Liu CY; Yu RL
    PLoS One; 2019; 14(3):e0214146. PubMed ID: 30897147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease.
    Muellner J; Gharrad I; Habert MO; Kas A; Martini JB; Cormier-Dequaire F; Tahiri K; Vidailhet M; Meier N; Brice A; Schuepbach M; Mallet A; Hartmann A; Corvol JC
    Parkinsonism Relat Disord; 2015 May; 21(5):471-6. PubMed ID: 25753458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Gray Matter Volume Loss in MAPT H1H1
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Front Neurol; 2018; 9():394. PubMed ID: 29899731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication.
    Yoritaka A; Hattori N; Yoshino H; Mizuno Y
    J Neural Transm (Vienna); 1997; 104(11-12):1313-7. PubMed ID: 9503277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease.
    Bayram E; Litvan I; Wright BA; Grembowski C; Shen Q; Harrington DL
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2021 Nov; 28(6):812-828. PubMed ID: 33021874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease.
    Bejr-Kasem H; Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Eur J Neurol; 2021 Feb; 28(2):438-447. PubMed ID: 33032389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.